Over 90 Total Lots Up For Auction at One Location - WA 04/08

NorthStar Medical Radioisotopes unveils advanced radioisotope production equipment, starts radioisotope production facility

Press releases may be edited for formatting or style | October 15, 2021 Business Affairs Molecular Imaging
BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, hosted a growth and production expansion event, “Accelerating the Future of Patient Health,” at its headquarters in Beloit, Wis., on September 23, 2021. The event showcased the completion of NorthStar’s Accelerator Production and Isotope Processing facilities, which involved the installation of cutting-edge radioisotope production and processing equipment, and a groundbreaking celebration for its new state-of-the-art Therapeutic Radioisotope Production facility. Numerous guest speakers from national, state and local organizations joined with industry and healthcare leaders, NorthStar customers and investors to share perspectives on the exciting growth of nuclear medicine, the need for reliable U.S. radioisotope supply to support patient health and their experiences with NorthStar.

Guest speakers included:

Keynote speaker Jeffrey Chamberlin, Associate Assistant Deputy Administrator for Material Management and Minimization, U.S. Department of Energy’s National Nuclear Security Administration, Washington, D.C.
stats
DOTmed text ad

Your Centrifuge Specialty Store

Quality remanufactured Certified Centrifuges at Great prices! Fully warranted and backed by a company you can trust! Call or click for a free quote today! www.Centrifugestore.com 800-457-7576

stats

Diane M. Hendricks, Chairperson, Hendricks Holding Co., Inc.
Lori S. Curtis Luther, City Manager, City of Beloit, Wis.
Alan B. Packard, PhD, FSNMMI, Immediate Past President, Society of Nuclear Medicine and Molecular Imaging (SNMMI), Boston Children’s Hospital/Harvard Medical School, Boston, Mass.
Randall C. Thompson, MD, FASNC, President, American Society of Nuclear Cardiology (ASNC), Professor of Medicine, University of Missouri-Kansas City School of Medicine, Saint Luke's Cardiovascular Consultants, Kansas City, Mo.
Alan Taylor, PhD, Executive Chairman, Clarity Pharmaceuticals, Sydney, Australia
Chris Vessell, U.S. Nuclear Medicine Supply Chain Leader, GE Healthcare, Arlington Heights, Ill.
Tressa Snow, BS, CNMT, Nuclear Medicine Technologist, Beloit Health System
Danny R. Allen, BCNP, President, NuTech Inc., Tyler, Texas
NorthStar Medical Radioisotopes is the sole commercial U.S. producer of the important medical radioisotope molybdenum-99 (Mo-99), and the only company in the world to use environmentally sound production processes that are non-uranium based. Mo-99 is used to generate technetium-99m (Tc-99m), which informs healthcare decisions for 40,000 U.S. patients daily. For nearly three years, NorthStar has provided the United States with reliable Mo-99 supply, used in its RadioGenix® System (technetium Tc 99m generator) to produce Tc-99m. NorthStar estimates that more than 1 million patients will have been diagnosed by the end of 2021 using NorthStar technology.

You Must Be Logged In To Post A Comment